The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.